SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.



Top 14 stocks in focus today: HDFC Bank, Shalby, IDBI Bank

HDFC Bank announced that its board will meet on December 20 to consider a proposal for raising of funds by issue of equity shares/ depository receipts and other securities including through QIP/ ADRs / preferential allotment or such other methods or combinations as may be decided, as well as a preferential issue to HDFC (the promoter).

Mahindra & Mahindra said it will increase prices of its passenger and commercial vehicles by up to 3% from January.

HDFC has sold 1.29cr shares of Unitech in the open market and invoked nearly 8.2cr pledged shares of the crisis-hit realty firm.

Natco Pharma has raised Rs915cr through issue of securities to qualified institutional investors.

Punjab National Bank and Union Bank of India have cumulatively raised Rs7,000cr through qualified institutional placement.

L&T said it has commissioned a 225 MW power plant in Bangladesh.

Gulf Oil Lubricants said that the commercial production for manufacturing of lubricants oil commenced from December 14 at the company’s new set-up plant at Chennai. The installed manufacturing capacity of the new plant is 50,000 KL per annum.

Tata Motors said it has delivered the first set of Tigor Electric Vehicles (EVs) to state-run Energy Efficiency Services Limited (EESL) as part of their initiative to procure 10,000 electric vehicles.

Fitch Ratings has placed IDBI Bank on ‘rating watch evolving’ and said that it sees potential of upward movement in the state-run lender’s viability rating by at least a notch.

Godrej Industries approves merger of Vora Soaps with company.

Dr. Reddy’s Labs gets US FDA nod for Valganciclovir Hydrochloride tablets (an antiviral used to treat cytomegalovirus infection), as per media reports.

Cadila Healthcare has received US FDA nod for Metronidazole (250-500 mg) tablets (used to treat pelvic inflammatory disease, endocarditis)

IDBI Trusteeship sold 1.1cr shares or 6.3% stake at Rs 58.5 each of Religare Enterprises.

Astrazeneca Pharma India announced that subject to the receipt of Import License from the Drugs Controller General of India, the FDC of Dapagliflozin + Metformin Hydrochloride film coated tablets (XIGDUO XR) is expected to be launched in India in Q4 of FY 2017-18.